On March 24, 2026, leaders from academia and industry convened for the Accelerating Cancer Cures Research Symposium, hosted by Amgen in Cambridge, Massachusetts. This event marked a significant gathering of minds dedicated to transforming the landscape of cancer treatment.
The Accelerating Cancer Cures Initiative
The Accelerating Cancer Cures (ACC) initiative is a multi-million-dollar collaborative project that aims to propel a new generation of clinical investigators. Established in 2011 and spearheaded by the Damon Runyon Cancer Research Foundation, ACC unites notable organizations such as AbbVie, Amgen, and Novartis, along with scientists from top universities and research institutes. The annual symposium serves as a platform to enhance communication and foster collaboration between cancer researchers in both industry and academia.
Insights from Industry Leaders
The symposium commenced with welcoming remarks from key figures including Yung S. Lie, PhD, President and CEO of Damon Runyon; Richard B. Gaynor, MD, President of Research and Development at BioNTech; and James Bradner, MD, Executive Vice President of Research and Development at Amgen. Dr. Bradner emphasized the exceptional talent cultivated by Damon Runyon, likening its scientists to an elite team. This acknowledgment highlights the organization’s role in nurturing the next generation of leaders in oncology.
Research Updates from Damon Runyon Scientists
Following the opening remarks, several Damon Runyon scientists presented their findings, contributing to a deeper understanding of cancer genomics. Mark Yarmarkovich, PhD, Lucas Farnung, PhD, Mary M. Mullen, MD, and Ziyang Zhang, PhD, shared their progress toward developing targeted therapies, underscoring the importance of molecular insights in combating cancer.
Keynote Address: Bridging Laboratory Science and Clinical Application
A highlight of the symposium was the keynote address by Anna Farago, MD, PhD, and Julie Bailis, PhD, both from Amgen. They discussed the critical connection between preclinical data and clinical outcomes, which facilitates the advancement of new therapies. Dr. Bailis articulated the necessity of integrating laboratory science with clinical research, emphasizing that this dialogue is essential for successful therapeutic development.
Exploring New Therapeutic Avenues
The symposium included presentations from additional Damon Runyon researchers, such as Megan A. Morrissey, PhD, Srivatsan Raghavan, MD, PhD, and Jonathan Chou, MD, PhD. Each researcher is investigating innovative approaches to treat challenging cancers, including pancreatic cancer. Their work exemplifies the ongoing quest to find effective solutions for the most difficult cancer types.
Collaborative Discussions on Breakthrough Therapies
In a thought-provoking fireside chat moderated by Catherine Sabatos-Peyton, PhD, key industry representatives discussed the pathways to developing breakthrough therapies. Jennifer Lauchte, MD, from Novartis, stressed the importance of multidisciplinary collaboration in clinical trials. She argued that involving a diverse team enhances the likelihood of success in drug development, reinforcing the notion that collaboration is key to innovation.
Conclusion: The Power of Collaboration in Cancer Research
The Accelerating Cancer Cures initiative illustrates the immense potential that arises from collaboration between academic researchers and industry professionals. By combining their unique insights and expertise, these groups can inspire innovative research and accelerate the development of new therapeutics. As Dr. Margaret Faul, VP of Drug Substance Technologies at Amgen, noted, dialogue between disciplines is vital for advancing patient care. The future of cancer treatment looks promising, driven by the collective efforts of these dedicated individuals.
- The ACC initiative fosters collaboration between academia and industry for cancer research.
- Keynote speakers emphasized the importance of linking laboratory findings with clinical applications.
- Multidisciplinary teams in clinical trials can enhance drug development success.
- Damon Runyon scientists are making significant strides in targeted cancer therapies.
- The symposium serves as a vital platform for sharing insights and advancing cancer research.
Read more → www.news-medical.net